Rouba Kozak - Publications

Pfizer, Inc., San Diego, CA, United States 

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Moore TL, Young DA, Killiany RJ, Fonseca KR, Volfson D, Gray DL, Balice-Gordon R, Kozak R. The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey. Frontiers in Aging Neuroscience. 13: 757850. PMID 34899271 DOI: 10.3389/fnagi.2021.757850  0.475
2020 Kozak R, Kiss T, Dlugolenski K, Johnson DE, Gorczyca RR, Kuszpit K, Harvey BD, Stolyar P, Sukoff Rizzo SJ, Hoffmann WE, Volfson D, Hajós M, Davoren JE, Abbott AL, Williams GV, et al. Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation. Frontiers in Pharmacology. 11: 1005. PMID 32733245 DOI: 10.3389/Fphar.2020.01005  0.435
2020 Balice-Gordon R, Honey GD, Chatham C, Arce E, Duvvuri S, Naylor MG, Liu W, Xie Z, DeMartinis N, Harel BT, Braley GH, Kozak R, Park L, Gray DL. A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity. The International Journal of Neuropsychopharmacology. PMID 32055822 DOI: 10.1093/Ijnp/Pyaa007  0.366
2020 Young D, Popiolek M, Trapa P, Fonseca KR, Brevard J, Gray DL, Kozak R. D1 agonist improved movement of parkinsonian nonhuman primates with limited dyskinesia side effects. Acs Chemical Neuroscience. PMID 31971364 DOI: 10.1021/acschemneuro.9b00589  0.488
2020 Soutschek A, Kozak R, de Martinis N, Howe W, Burke CJ, Fehr E, Jetter A, Tobler PN. Activation of D1 receptors affects human reactivity and flexibility to valued cues. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31962344 DOI: 10.1038/S41386-020-0617-Z  0.669
2019 Arce E, Balice-Gordon R, Duvvuri S, Naylor M, Xie Z, Harel B, Kozak R, Gray DL, DeMartinis N. A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia. Journal of Psychopharmacology (Oxford, England). 269881119855302. PMID 31264510 DOI: 10.1177/0269881119855302  0.375
2019 Wang M, Datta D, Enwright J, Galvin V, Yang ST, Paspalas C, Kozak R, Gray DL, Lewis DA, Arnsten AFT. A novel dopamine D1 receptor agonist excites delay-dependent working memory-related neuronal firing in primate dorsolateral prefrontal cortex. Neuropharmacology. PMID 30858103 DOI: 10.1016/J.Neuropharm.2019.03.001  0.384
2018 Davoren JE, Nason DM, Coe J, Dlugolenski K, Helal CJ, Harris AR, LaChapelle E, Liang S, Liu Y, O'Connor RE, Orozco CC, Rai BK, Salafia M, Samas BM, Xu W, ... Kozak R, et al. Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization. Journal of Medicinal Chemistry. PMID 30431269 DOI: 10.1021/Acs.Jmedchem.8B01622  0.317
2018 Gilmour G, Porcelli S, Bertaina-Anglade V, Arce E, Dukart J, Hayen A, Lobo A, Lopez Anton R, Merlo Pich E, Pemberton DJ, Havenith MN, Glennon J, Harel B, Dawson G, Marston H, ... Kozak R, et al. Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. Neuroscience and Biobehavioral Reviews. PMID 30399355 DOI: 10.1016/J.Neubiorev.2018.09.025  0.338
2018 Popiolek M, Mandelblat-Cerf Y, Young D, Garst-Orozco J, Lotarski SM, Stark E, Kramer M, Butler CR, Kozak R. In vivo modulation of hippocampal excitability by M4 muscarinic acetylcholine receptor activator: implications for treatment of Alzheimer's disease and schizophrenic patients. Acs Chemical Neuroscience. PMID 30335349 DOI: 10.1021/acschemneuro.8b00496  0.462
2018 Gray DL, Allen JA, Mente S, O'Connor RE, DeMarco GJ, Efremov I, Tierney P, Volfson D, Davoren J, Guilmette E, Salafia M, Kozak R, Ehlers MD. Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. Nature Communications. 9: 674. PMID 29445200 DOI: 10.1038/s41467-017-02776-7  0.346
2018 Howe WM, Brooks JL, Tierney PL, Pang J, Rossi A, Young D, Dlugolenski K, Guillmette E, Roy M, Hales K, Kozak R. α5 nAChR modulation of the prefrontal cortex makes attention resilient. Brain Structure & Function. PMID 29299690 DOI: 10.1007/s00429-017-1601-1  0.732
2017 Koola MM, Sklar J, Davis W, Nikiforuk A, Meissen JK, Sawant-Basak A, Aaronson ST, Kozak R. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments. Schizophrenia Research. PMID 28705532 DOI: 10.1016/J.Schres.2017.07.005  0.368
2017 Popiolek M, Tierney PL, Young D, Lotarski S, Kozak R. FUNCTIONAL AND PHARMACOLOGICAL CHARACTERIZATION OF A NOVEL AND SELECTIVE MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ACTIVATOR Alzheimer's & Dementia. 13: P946. DOI: 10.1016/j.jalz.2017.06.1857  0.462
2016 Howe WM, Young DA, Bekheet G, Kozak R. Nicotinic receptor subtypes differentially modulate glutamate release in the dorsal medial striatum. Neurochemistry International. PMID 27568861 DOI: 10.1016/j.neuint.2016.08.009  0.692
2015 Mohler EG, Ding Z, Rueter LE, Chapin D, Young D, Kozak R. Cross-site strain comparison of pharmacological deficits in the touchscreen visual discrimination test. Psychopharmacology. PMID 26177580 DOI: 10.1007/s00213-015-4012-0  0.515
2015 Yohn SE, Santerre JL, Nunes EJ, Kozak R, Podurgiel SJ, Correa M, Salamone JD. The role of dopamine D1 receptor transmission in effort-related choice behavior: Effects of D1 agonists. Pharmacology, Biochemistry, and Behavior. 135: 217-26. PMID 26022661 DOI: 10.1016/J.Pbb.2015.05.003  0.341
2015 Howe WM, Tierney PL, Young DA, Oomen C, Kozak R. MAM (E17) rodent developmental model of neuropsychiatric disease: disruptions in learning and dysregulation of nucleus accumbens dopamine release, but spared executive function. Psychopharmacology. PMID 25963563 DOI: 10.1007/s00213-015-3955-5  0.725
2015 Howe W, Tierney PL, Rossi A, Young D, Guillmette E, Kozak R. 2.14α5 nAChR modulation of the effects of nicotine on ventral-striatal DA release and cue-reward learning Biochemical Pharmacology. 97: 634-635. DOI: 10.1016/J.Bcp.2015.08.039  0.692
2014 Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM, Fonseca K, Guanowsky V, Young DA, Seymour PA, Dounay A, et al. Reduction of brain kynurenic acid improves cognitive function. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 10592-602. PMID 25100593 DOI: 10.1523/Jneurosci.1107-14.2014  0.573
2014 Koshy Cherian A, Gritton H, Johnson DE, Young D, Kozak R, Sarter M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology. 82: 41-8. PMID 24647121 DOI: 10.1016/j.neuropharm.2014.03.004  0.738
2013 Lustig C, Kozak R, Sarter M, Young JW, Robbins TW. CNTRICS final animal model task selection: control of attention. Neuroscience and Biobehavioral Reviews. 37: 2099-110. PMID 22683929 DOI: 10.1016/J.Neubiorev.2012.05.009  0.584
2011 Roof R, Siok C, Hajos M, Cianfrogna J, Chang C, Leung L, Duplantier A, Brodney M, McDowell L, Prior F, Vanase-Frawley M, McGinnis D, Kozak R, Seymour P, Leurent C, et al. A selective ORL1 antagonist enhances hippocampal function and reverses pharmacologically induced cognitive deficits in rodents Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.2220  0.369
2009 Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochemical Pharmacology. 78: 813-24. PMID 19501054 DOI: 10.1016/J.Bcp.2009.05.033  0.379
2009 Sarter M, Martinez V, Kozak R. A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. Psychopharmacology. 202: 237-58. PMID 18618100 DOI: 10.1007/s00213-008-1216-6  0.671
2007 Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron. 56: 141-54. PMID 17920021 DOI: 10.1016/j.neuron.2007.08.025  0.717
2007 Kozak R, Martinez V, Young D, Brown H, Bruno JP, Sarter M. Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 2074-86. PMID 17299502 DOI: 10.1038/sj.npp.1301352  0.725
2006 Sarter M, Bruno JP, Parikh V, Martinez V, Kozak R, Richards JB. Forebrain dopaminergic-cholinergic interactions, attentional effort, psychostimulant addiction and schizophrenia. Exs. 98: 65-86. PMID 17019883  0.702
2006 Parikh V, Apparsundaram S, Kozak R, Richards JB, Sarter M. Reduced expression and capacity of the striatal high-affinity choline transporter in hyperdopaminergic mice. Neuroscience. 141: 379-89. PMID 16675138 DOI: 10.1016/J.Neuroscience.2006.03.055  0.664
2006 Sarter M, Gehring WJ, Kozak R. More attention must be paid: the neurobiology of attentional effort. Brain Research Reviews. 51: 145-60. PMID 16530842 DOI: 10.1016/j.brainresrev.2005.11.002  0.58
2006 Kozak R, Bruno JP, Sarter M. Augmented prefrontal acetylcholine release during challenged attentional performance. Cerebral Cortex (New York, N.Y. : 1991). 16: 9-17. PMID 15788700 DOI: 10.1093/cercor/bhi079  0.596
2005 Apparsundaram S, Martinez V, Parikh V, Kozak R, Sarter M. Increased capacity and density of choline transporters situated in synaptic membranes of the right medial prefrontal cortex of attentional task-performing rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 3851-6. PMID 15829637 DOI: 10.1523/Jneurosci.0205-05.2005  0.712
Show low-probability matches.